New Regulations on Cough Syrups: Prescription Required for Sale

In a significant move to enhance drug safety, the Union Health Ministry of India has mandated that cough syrups can only be sold with a doctor's prescription. This regulation aims to improve oversight of syrup-based medications following concerns about quality and contamination. The new rules, effective immediately, remove syrups from the exempt drug categories, ensuring stricter compliance from manufacturers and sellers. This decision follows public feedback and consultations with the Drugs Technical Advisory Board, reflecting a commitment to patient safety amid rising scrutiny of liquid oral formulations. Read on to learn more about these important changes.

By Narendra Chaudhary Jun 16, 2026, 12:45 IST

New Health Regulations for Syrup Sales

A carton of cough syrup bottles. Image used for representational purposes only. (Photo:@CMOfficeAssam/X)

New Delhi, Jun 16: In response to growing concerns regarding drug quality and patient safety, the Union Health Ministry has introduced new regulations that require a doctor's prescription for the sale of syrups, including cough syrups.

This initiative aims to place syrup-based products, such as cough syrups, under more stringent regulatory control, according to official sources.

The changes were formalized through the Drugs (Fifth Amendment) Rules, 2026, which have been published in the official gazette and are effective immediately.

As per the notification from the Ministry of Health and Family Welfare, the term "syrups" has been removed from item 7 in the "Class of Drugs" section of Schedule K of the Drugs Rules, 1945.

Schedule K outlines drug categories that are exempt from specific manufacturing, sales, and distribution regulations under the Drugs and Cosmetics Act, provided certain conditions are met.

This amendment follows a draft notification released by the government in December of the previous year, which invited feedback from stakeholders.

The ministry has stated that public comments were taken into account before finalizing the amendment, following consultations with the Drugs Technical Advisory Board (DTAB), the nation's primary authority on drug-related technical issues.

This decision is part of a broader effort to enhance regulatory oversight of cough syrups and other liquid oral medications, especially in light of reports linking contamination to child fatalities in various countries.

Sources indicate that the new regulations are expected to improve traceability and regulatory oversight of syrup-based medications, ensuring that manufacturers and sellers adhere to more rigorous licensing and quality control standards.